Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas
{"title":"水杨醛亚胺锌复合物的结构研究及抗菌、抗真菌和抗癌研究。","authors":"Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas","doi":"10.1080/17568919.2024.2363672","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Zinc salicylaldimines may act as multidrug agents.<b>Results:</b> Three zinc salicylaldimines <b>C1-C3</b> and respective ligands <b>HL<sup>1</sup></b>-<b>HL<sup>3</sup></b> were examined for antimicrobial/anticancer drug action and <b>C3</b> was structurally analyzed (tetrahedral, triclinic). Against two fungi, <b>C1</b> inhibited <i>Candida albicans</i> with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.<b>Conclusion:</b> The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1551-1560"},"PeriodicalIF":3.2000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370977/pdf/","citationCount":"0","resultStr":"{\"title\":\"Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes.\",\"authors\":\"Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas\",\"doi\":\"10.1080/17568919.2024.2363672\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Zinc salicylaldimines may act as multidrug agents.<b>Results:</b> Three zinc salicylaldimines <b>C1-C3</b> and respective ligands <b>HL<sup>1</sup></b>-<b>HL<sup>3</sup></b> were examined for antimicrobial/anticancer drug action and <b>C3</b> was structurally analyzed (tetrahedral, triclinic). Against two fungi, <b>C1</b> inhibited <i>Candida albicans</i> with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.<b>Conclusion:</b> The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.</p>\",\"PeriodicalId\":12475,\"journal\":{\"name\":\"Future medicinal chemistry\",\"volume\":\" \",\"pages\":\"1551-1560\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370977/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17568919.2024.2363672\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2363672","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes.
Aim: Zinc salicylaldimines may act as multidrug agents.Results: Three zinc salicylaldimines C1-C3 and respective ligands HL1-HL3 were examined for antimicrobial/anticancer drug action and C3 was structurally analyzed (tetrahedral, triclinic). Against two fungi, C1 inhibited Candida albicans with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited Staphylococcus aureus and Escherichia coli (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.Conclusion: The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.
期刊介绍：
Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
